Pharmaceuticals

EnGeneIC Announces Publication in Cancer Cell of a Scientific Paper Highlighting the Ability of EDV™ Nanocells to Mount Dual Assault on Cancer Cells

EDV™ Technology Stimulates Both Innate and Adaptive Immune Response and Confers Long-Term Survival Research Paves Way for Treatment of Drug-Resistant, End-Stage Cancers NEW YORK and SYDNEY, March 17, 2020 /PRNewswire/ -- EnGeneIC Limited, a clinical-stage biopharmaceutical company advancing its ...

2020-03-17 00:35 2037

China SXT Pharmaceuticals, Inc. Announces That It Received a Grant Supported by City Government

TAIZHOU, China, March 16, 2020 /PRNewswire/ -- China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC ) ("China SXT" or the "Company"), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales o...

2020-03-16 21:16 5055

China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2019

BEIJING, March 12, 2020 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced its financial results for the fourth quarter and fiscal year of 2019. Fourt...

2020-03-13 05:00 10296

NDA Filing for Luye Pharma's Antidepressant Drug LY03005 Accepted by the U.S. FDA

SHANGHAI, March. 4, 2020 /PRNewswire/ -- Luye Pharma Group has announced that the U.S. Food and Drug Administration (FDA) has reviewed and accepted the filing of a New Drug Application (NDA) for LY03005, a new chemical drug for the treatment of major depressive disorder. LY03005 is the company's ...

2020-03-04 21:27 2109

China Biologic Products to Report Fourth Quarter and Fiscal Year 2019 Financial Results

BEIJING, March 3, 2020 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced that the Company plans to release its fourth quarter and fiscal year 2019 fi...

2020-03-03 21:30 7817

Samsung Biologics and STCube Enter into Development and Manufacturing Agreement for Novel Target Anticancer Drug

SONGDO, South Korea, March 2, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) and STCube announced a strategic development and manufacturing service agreement for STT-003 antibody, an anti-cancer drug candidate. Under the agreement, Samsung Biologics will offer a wide range of services from c...

2020-03-03 03:00 1267

Yuyu Pharma announces review of compliance policies and procedures

SEOUL, South Korea, March 2, 2020 /PRNewswire/ -- Yuyu Pharma (COO Robert Wonsang Yu, KRX 000220) announced today a review of its compliance policies and procedures with the support of the law firm, Kim & Chang. The Kim & Chang project team, consisting of 6 lawyers and 1 expert advisor, implement...

2020-03-02 22:00 1229

China Pharmaceutical Holdings Co., Ltd. Launched A New Product

HAIKOU CITY, China, March 2, 2020 /PRNewswire/ -- China Pharmaceutical Holdings Limited (NYSE American: CPHI) ("China Pharma" or "Company"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based inChina, today announced that its subsidiary, Hainan ...

2020-03-02 20:00 6033

Samsung Biologics Confirms 'No Impact' of COVID-19 with Business Continuity Plan in Effect

SONGDO, South Korea, Feb. 24, 2020 /PRNewswire/ -- Samsung Biologics has been monitoring the COVID-19 situation closely since the initial outbreak in late January and taking proactive measures company-wide to ensure a safe working environment and continuous business operations. The company confi...

2020-02-27 15:49 1550

WuXi Diagnostics' integrated testing solution for COVID-19 epidemiological investigation and diagnosis

SHANGHAI, Feb. 27, 2020 /PRNewswire/ -- WuXi Diagnostics has successfully developed a series of COVID-19 detection products, including2019-nCoV IgM Detection kit (Enzyme-linked Immunoassay, ELISA), 2019-nCoV IgM/IgG Detection Kit (Enzyme-linked Immunoassay, ELISA) and 2019-nCoV Nucleic Acid Detec...

2020-02-27 15:47 1917

Ascentage Pharma Announces Approval for the Phase Ib/II Clinical Trial of APG-1387 in Combination with Chemotherapy for the Treatment of Advanced Pancreatic Cancer in China

SUZHOU, China and ROCKVILLE, MD., Feb. 24, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally-focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the company has receive...

2020-02-24 22:00 2423

WuXi Biologics Congratulates Immutep on Positive Interim Data for IMP-321

SHANGHAI, Feb. 23, 2020 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, congratulates its strategic partner Immutep, a biotechnology comp...

2020-02-24 08:00 6131

VolitionRx Limited Announces Full Fiscal Year 2019 Financial Results and Business Update

AUSTIN, Texas, Feb. 20, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the full fiscal year endedDecember 31, 2019. Volition management will host a conference call tomorrow,February 21, at 8:30 a.m. U.S. Easte...

2020-02-21 05:10 10105

StoneWise AI-driven Drug Discovery Platform: Investigation and Repurpose of Nucleoside-based RNA Polymerase Inhibitors and Their Potential Use in COVID-19 Infection Treatment

BEIJING, Feb. 20, 2020 /PRNewswire/ -- In a campaign to screen drugs for the treatment of COVID-19, the disease caused by SARS-CoV-2, StoneWise, a company specialized in applying artificial intelligence to innovative drug design solutions for innovative drug R&D enterprises and institutions, has ...

2020-02-20 20:04 1408

111 Partners with Financial Institutions in Battle Against Coronavirus

SHANGHAI, Feb. 20, 2020 /PRNewswire/ -- 111, Inc. (NASDAQ: YI, "111" or the "Company") has announced that it will leverage its knowhow and technology in the battle against the novel coronavirus (COVID-19) public health crisis, through partnerships with some ofChina's leading financial institution...

2020-02-20 17:00 5339

VolitionRx Limited Schedules Full Year 2019 Earnings Conference Call and Business Update

AUSTIN, Texas, Feb. 18, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call onFriday, February 21 at 8:30 a.m. Eastern time to discuss its financial and operating results for the fourth quarter and full year 2019, in conjunctio...

2020-02-19 05:10 10244

Ally Bridge Group Leads US$70 million Investments in Two Israeli Life Science Companies over the Last 2 Months

TEL AVIV, Israel, HONG KONG and NEW YORK, Feb. 18, 2020 /PRNewswire/ — Ally Bridge Group ("ABG"), a leading global life science investment group, has announced that it recently ledUS$70 million investments in two Israeli life science companies over the last 2 months. Each of the two companies is ...

2020-02-18 21:30 1798

Volition Unveils Its Epigenetic Toolbox

AUSTIN, Texas, Feb. 18, 2020 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that research on its Nu.Q(TM) Capture program has led to the development of a suite of novel epigenetic tools building on the breakthroughs announced last month on its assay platform...

2020-02-18 21:30 8611

Immuron reports diarrhea no.1 health issue for Americans on vacation

NEW YORK, Feb. 12, 2020 /PRNewswire/ -- Diarrhea remains the top health issue facing Americans traveling to high risk countries, affecting 30 to 70 per cent of travelers depending upon their destination, according to biopharmaceutical company Immuron Limited[1], [2].

2020-02-13 04:35 1184

GC Pharma Reports Full Year 2019 Results

All consolidated entities revenues grew plus compared to prior year YONGIN, South Korea, Feb. 12, 2020 /PRNewswire/ -- GC Pharma (formerly known as Green Cross Corporation) (KRX: 006280), a South Korean biopharmaceutical company, today announced unaudited results for the year ended31 December 201...

2020-02-12 22:00 9961